Isa-CAPED MM: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone (Isa-KPd) for Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Dec 2021 Planned End Date changed from 31 Dec 2028 to 31 Dec 2029.
- 09 Dec 2021 Planned primary completion date changed from 31 Dec 2028 to 31 Dec 2029.
- 21 Jul 2021 Status changed from not yet recruiting to recruiting.